In a significant blow to the Philadelphia Phillies’ early-season plans, outfielder Johan Rojas has been suspended for 80 games by Major League Baseball after testing positive for a performance-enhancing drug. The league made the announcement late Monday, confirming that Rojas tested positive for Boldenone, an anabolic steroid, which is strictly prohibited under the MLB Joint Drug Prevention and Treatment Program.
The suspension throws a wrench into the Phillies’ carefully constructed outfield plans and casts a shadow over the 25-year-old’s career, just as he was looking to redefine his role with the club.
Rojas’s positive test was first reported a few weeks ago, at which point he opted to appeal the decision. That appeal has now been heard and rejected, making the discipline final. The 80-game ban will commence immediately at the start of the 2026 regular season, sidelining Rojas for nearly half the year. He will not be eligible to return until deep into the summer, and crucially, players suspended for PED use are barred from postseason participation, meaning that even if the Phillies make a deep playoff run, Rojas will have no part in it.
A Career at a Crossroads
For Rojas, the suspension arrives at a pivotal moment in his young career. Since bursting onto the scene, he has been a tantalizing blend of elite defensive tools and raw, undeveloped offensive skills. He has served as Philadelphia’s primary center fielder for significant stretches over the past three seasons, earning rave reviews for his glove work and his game-changing speed on the basepaths. In an era where premium defense up the middle is highly coveted, Rojas’s ability to track down balls in the gaps has made him a valuable asset.
However, his bat has consistently failed to catch up to his glove. Since the start of the 2024 campaign, Rojas has struggled immensely at the plate, slashing just .237/.279/.312. That production translates to a 64 wRC+ (weighted Runs Created Plus), a statistic that measures a player’s offensive output adjusted for their ballpark and league conditions. A score of 100 is league average; Rojas’s 64 indicates he has been a staggering 36 percent below average offensively. His on-base percentage, a paltry .279 over that stretch, has been a particular area of concern, making it difficult for him to leverage his primary weapon—his speed.
The PED suspension now adds a new and troubling dimension to his profile. It raises unavoidable questions about whether the pressure to improve his offensive output, and thus secure his place in a contending lineup, led him to make a poor decision. The use of Boldenone, a substance known for building muscle mass and aiding recovery, suggests an attempt to add the power and strength his slight frame has lacked.
The Phillies’ Shifting Plans
The Phillies’ front office had already begun to move on from the idea of Rojas as an everyday player, largely due to his offensive shortcomings. At the trade deadline last season, they acquired veteran center fielder Harrison Bader, a defensive specialist in a similar mold. Bader departed in free agency over the winter, but the organization made it clear they were ready to turn the page internally.
All signs pointed to top prospect Justin Crawford, the speedy son of former MLB star Carl Crawford, being given the keys to center field on Opening Day. Crawford represents the future of the position, and the team was eager to see if his hitting acumen could translate to the major league level.
In this context, Rojas’s role for 2026 was murky at best. He appeared destined for a reserve role, serving as a late-inning defensive replacement and a pinch-running specialist. At worst, he might have been ticketed for Triple-A to get regular at-bats, serving as the first option should Crawford struggle against big-league pitching. This suspension eliminates that safety net entirely.
An Immediate Roster Crisis
The absence of Rojas for the first half of the season leaves the Phillies with a noticeable lack of depth in center field. While Crawford is now the undisputed starter, the backup options are thin and unproven.
Left fielder Brandon Marsh has experience in center and could theoretically slide over in a pinch, but defensive metrics and the eye test both suggest he is stretched thin as an everyday option there. Behind him, the 40-man roster offers little comfort. Pedro León, acquired for his raw power and arm strength, has appeared in just seven major league games and is still adjusting to professional baseball in North America.
Veteran utility man Dylan Moore, known for his defensive versatility, has some limited experience in center field. However, he is not currently on the 40-man roster. The Phillies could select his contract to add him as a multi-positional bench piece, providing coverage at second base, shortstop, and the outfield, but that would require a corresponding roster move.
Looking for External Help
With Opening Day just weeks away, the Phillies’ front office may be forced to scan the waiver wire and the free-agent market for a stopgap solution. As teams across the league finalize their 26-man rosters, a wave of veterans will inevitably be designated for assignment or granted free agency. This “waiver wire season” often yields useful role players, and Philadelphia could capitalize on it to add a defensively capable fourth outfielder who can provide cover behind Crawford.
For now, the Johan Rojas suspension is a stark reminder of the risks and consequences within MLB’s drug program. It sidelines a talented player at a critical juncture, creates an unforeseen headache for a team with World Series aspirations, and leaves Rojas himself with a long road to rebuild his reputation and reclaim his place in the organization once his 80-game sentence is served.
